Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Immune-onc Therapeutics Inc.
Headquarters: Palo Alto, CA, United States of America
Website: http://www.immune-onc.com
Year Founded: 2016
Status: Private
BioCentury | Sep 17, 2024
Management Tracks
Peter Maag resigns as Kyverna CEO
Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 18, 2022
Finance
East-West Summit Highlights, Part 2: a BioCentury podcast
Agio Capital’s Henk Joos, Immune-Onc’s Charlene Liao discuss navigating the ‘biotech winter’
BioCentury | Nov 15, 2022
Product Development
Annual BayHelix awards highlight China’s maturing life sciences sector
Legend, Insilico, Turning Point, Immune-Onc among winners; Joan Shen named Woman Leader of Year
BioCentury | Jul 14, 2022
Management Tracks
New CEO at Deerfield-backed Apertura
Plus 10x Genomics hires Wilbur to head commercial, and updates from Immune-Onc, PathAI, Sherlock and more
BioCentury | Apr 26, 2022
Management Tracks
Stoffels becomes Galapagos board chairman
Plus Vedere Bio II and management moves at Jnana, Flare, DeepCure and more
BioCentury | Nov 13, 2021
Discovery & Translation
Repare identifies new BRCA synthetic lethal relationship; plus Immune-Onc, Acuitas and more
BioCentury’s roundup of translational news
BioCentury | Mar 30, 2021
Finance
March 30 Quick Takes: BioNTech anticipates €9.8B year; plus Immune-Onc, Amgen-Rodeo, Stuart, Bond
BioNTech making plans around €9.8B year for vaccine salesWith estimated 2021 revenue of €9.8 billion ($11.5 billion) from sales of COVID-19 vaccine BNT162b2, BioNTech SE (NASDAQ:BNTX)
BioCentury | Feb 26, 2021
Emerging Company Profile
Immune-Onc building broad pipeline of myeloid checkpoint inhibitors
Emerging Company Profile: Founded by Guo-Liang Yu and Charlene Liao, the cancer play’s lead is a first-in-class ILT3 inhibitor
Items per page:
1 - 10 of 16